Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:24AM ET
6.85
Dollar change
-0.00
Percentage change
-0.01
%
Index- P/E- EPS (ttm)-1.32 Insider Own29.89% Shs Outstand84.87M Perf Week0.36%
Market Cap725.28M Forward P/E- EPS next Y-0.35 Insider Trans-3.64% Shs Float74.23M Perf Month-7.44%
Income-96.51M PEG- EPS next Q-0.15 Inst Own56.10% Short Float5.11% Perf Quarter118.13%
Sales10.66M P/S68.04 EPS this Y52.74% Inst Trans-6.30% Short Ratio1.73 Perf Half Y159.45%
Book/sh-0.14 P/B- EPS next Y47.77% ROA-189.48% Short Interest3.79M Perf Year735.29%
Cash/sh0.35 P/C19.36 EPS next 5Y- ROE-682.16% 52W Range0.76 - 9.39 Perf YTD104.46%
Dividend Est.- P/FCF- EPS past 5Y-8.72% ROI- 52W High-27.06% Beta1.81
Dividend TTM- Quick Ratio0.80 Sales past 5Y0.00% Gross Margin95.68% 52W Low804.69% ATR (14)0.59
Dividend Ex-Date- Current Ratio0.80 EPS Y/Y TTM59.67% Oper. Margin-586.31% RSI (14)62.72 Volatility6.94% 10.47%
Employees25 Debt/Eq- Sales Y/Y TTM- Profit Margin-905.38% Recom1.20 Target Price11.60
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-17.44% Payout- Rel Volume0.44 Prev Close6.85
Sales Surprise- EPS Surprise-114.25% Sales Q/Q- EarningsMar 06 BMO Avg Volume2.19M Price6.85
SMA204.94% SMA5043.24% SMA200150.34% Trades Volume174,574 Change-0.01%
Date Action Analyst Rating Change Price Target Change
Mar-26-24Initiated RBC Capital Mkts Outperform $12
Feb-22-24Initiated Leerink Partners Outperform $12
Jan-04-22Downgrade Barclays Overweight → Equal Weight $44 → $7
Aug-27-21Downgrade Goldman Neutral → Sell $16 → $10
Jun-25-21Resumed Goldman Neutral $18
Oct-08-20Initiated Truist Buy $85
Apr-22-20Initiated Goldman Buy $60
Feb-27-20Initiated Barclays Overweight $64
Jun-10-19Initiated Robert W. Baird Outperform $24
Jun-10-19Initiated Cowen Outperform
Mar-13-24 09:23AM
Mar-08-24 04:32AM
Mar-06-24 07:00AM
Feb-28-24 01:01PM
09:48AM
08:05AM Loading…
08:05AM
08:00AM
Feb-21-24 09:21AM
Feb-15-24 07:00AM
Jan-05-24 09:23AM
03:31AM
02:32AM
Jan-04-24 04:05PM
Jan-03-24 07:00AM
Nov-09-23 08:34AM
07:30AM Loading…
07:30AM
Nov-02-23 07:00AM
Nov-01-23 07:00AM
Oct-20-23 01:22PM
Sep-28-23 07:00AM
Sep-06-23 07:00AM
Aug-11-23 07:42AM
Aug-10-23 07:00AM
Jul-29-23 11:07AM
Jul-25-23 07:00AM
Jun-22-23 07:00AM
Jun-15-23 07:00AM
May-25-23 07:00AM
May-11-23 07:00AM
May-05-23 02:24PM
07:00AM Loading…
Apr-24-23 07:00AM
07:00AM
Mar-23-23 06:30AM
Mar-18-23 09:54AM
Mar-01-23 07:00AM
Feb-16-23 10:46AM
07:00AM
Feb-09-23 07:00AM
Jan-04-23 06:00AM
Nov-09-22 07:00AM
Oct-31-22 07:00AM
Oct-25-22 07:00AM
Oct-09-22 09:13AM
Oct-06-22 11:18AM
07:00AM
Sep-02-22 09:55AM
Aug-12-22 07:00AM
Jul-28-22 07:00AM
Jun-22-22 10:12PM
04:10PM
Jun-16-22 08:08AM
Jun-03-22 07:00AM
May-20-22 09:50AM
May-19-22 07:00AM
May-18-22 11:47AM
11:03AM
May-17-22 11:31AM
May-13-22 10:30AM
08:28AM
May-12-22 06:59AM
May-11-22 07:32AM
May-05-22 07:30AM
May-03-22 10:47AM
May-02-22 07:12AM
Apr-28-22 10:24AM
Apr-12-22 11:47AM
Apr-08-22 11:39AM
Apr-04-22 07:30AM
Mar-31-22 11:05AM
Mar-22-22 11:36AM
Mar-16-22 07:30AM
Mar-15-22 12:19PM
Mar-10-22 07:30AM
Mar-01-22 07:00AM
Feb-28-22 07:30AM
Feb-10-22 07:00AM
Jan-03-22 12:43PM
08:25AM
07:00AM
03:14AM
Dec-16-21 07:00AM
Nov-18-21 07:00AM
04:55AM
Nov-12-21 07:00AM
Oct-25-21 07:00AM
Oct-18-21 07:00AM
Oct-06-21 12:00PM
Sep-17-21 06:19AM
Sep-09-21 10:01AM
07:00AM
Aug-12-21 07:00AM
Jun-28-21 07:00AM
Jun-25-21 12:05PM
Jun-21-21 07:00AM
Jun-17-21 11:32AM
07:00AM
Jun-01-21 07:00AM
May-19-21 08:50PM
07:00AM
01:42AM
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shendelman ShoshanaPresident and CEOMar 14 '24Sale5.39318,5731,717,1083,817,814Mar 18 06:12 PM
Perfetti RiccardoChief Medical OfficerMar 14 '24Sale5.39110,804597,2341,031,537Mar 18 06:02 PM
Hansard AdamChief Commercial OfficerMar 14 '24Sale5.3948,871263,415732,919Mar 18 06:00 PM
Funtleyder Leslie D.Chief Financial OfficerMar 14 '24Sale5.3928,727154,839308,421Mar 18 05:57 PM
Kanter Stacy J.DirectorDec 01 '23Buy2.1830,00065,36763,000Dec 05 07:03 PM
Shendelman ShoshanaPresident and CEONov 30 '23Sale1.973,9687,8172,596,387Dec 01 07:42 PM
Perfetti RiccardoChief Medical OfficerNov 30 '23Sale1.971,5833,119692,341Dec 01 07:42 PM
Hansard AdamChief Commercial OfficerNov 30 '23Sale1.979651,901381,790Dec 01 07:42 PM
ALEXANDRIA REAL ESTATE EQUITIE10% OwnerNov 03 '23Sale2.31143,450331,3705,580,077Nov 06 04:56 PM
ALEXANDRIA REAL ESTATE EQUITIE10% OwnerNov 02 '23Sale2.32103,808240,8355,723,527Nov 06 04:56 PM
ALEXANDRIA REAL ESTATE EQUITIE10% OwnerNov 01 '23Sale2.36172,742407,6715,827,335Nov 02 04:44 PM
ALEXANDRIA REAL ESTATE EQUITIE10% OwnerOct 31 '23Sale2.41155,000373,5506,000,077Nov 02 04:44 PM
Shendelman ShoshanaPresident and CEOSep 27 '23Sale2.70115,632312,2062,600,355Sep 29 08:03 PM
Perfetti RiccardoChief Medical OfficerSep 27 '23Sale2.7010,93229,516693,924Sep 29 08:02 PM
Hansard AdamChief Commercial OfficerSep 27 '23Sale2.709,72026,244382,755Sep 29 08:02 PM
MARCUS JOEL SDirectorSep 15 '23Option Exercise1.0512,37512,994453,414Sep 19 08:08 PM